Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1

Trial Profile

A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2018

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DESTINY-Breast01
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 13 Sep 2018 Status changed from recruiting to active, no longer recruiting.
    • 31 Aug 2018 Biomarkers information updated
    • 11 Jun 2018 According to data presented at the 54th Annual Meeting of the American Society of Clinical Oncology, 35 (planned 230 subjects) have been enrolled as of Feb. 12, 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top